Study of Radiation Plus Pembrolizumab for Head and Neck Cancer

Share this content:
Researchers are evaluating the safety and efficacy of high or high and low radiation dosages combined with pembrolizumab for patients with advanced or metastatic head and neck cancer.
Researchers are evaluating the safety and efficacy of high or high and low radiation dosages combined with pembrolizumab for patients with advanced or metastatic head and neck cancer.

Title: Targeting PD-1 Therapy Resistance With Focused High or High and Low Dose Radiation in Squamous Cell Carcinoma of the Head and Neck (SCCHN)1

Principal Investigators: Jonathan D. Schoenfeld, MD, MPH, Dana-Farber Cancer Institute

Description: For this non-randomized, phase 2 trial (ClinicalTrials.gov Identifier: NCT03085719), researchers are evaluating the safety and efficacy of high or high and low radiation dosages combined with pembrolizumab for patients with advanced or metastatic head and neck cancer.

Patients will be assigned to receive high dose radiation and pembrolizumab or high dose plus low dose radiation and pembrolizumab. High radiation dosages will be administered in 3 fractions; low doses will be administered in 2 fractions.

The primary outcome is overall response rate; secondary outcomes include overall survival, progression-free survival, and rate of adverse events.

For more study information, including inclusion and exclusion criteria, study locations, and contact information, visit https://clinicaltrials.gov/ct2/show/NCT03085719.

Status: This study is open and recruiting patients as of May 9, 2017.

This study is sponsored by Dana-Farber Cancer Institute in collaboration with Merck Sharpe & Dohme Corp.

Reference

  1. Clinicaltrials.gov. Targeting PD-1 therapy resistance with focused high or high and low dose radiation in SCCHN. NCT03085719. https://clinicaltrials.gov/ct2/show/NCT03085719. Accessed May 9, 2017.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters